Last Update 26 May 26
AMPH: Reset Expectations May Set Stage For Future Upside
Narrative Update on Amphastar Pharmaceuticals
Analysts have reset Amphastar Pharmaceuticals' price target to $19 from $30. This revision reflects lower modeled revenue growth, reduced profit margin assumptions, a higher discount rate, and increased uncertainty around AMP-004's potential interchangeability status and the company's ability to meet its 2026 outlook.
Analyst Commentary
Recent Street research has shifted toward a more cautious stance on Amphastar Pharmaceuticals, with several firms revising ratings to more neutral positions and cutting price targets. The key concerns center on the uncertainty of revenue assumptions for 2026 and 2027, the challenge of meeting the company’s stated 2026 outlook, and the risk that AMP-004 may not achieve interchangeability status.
Earlier in the year, analysts were already reining in expectations as revenue guidance was revised and price targets were trimmed, even as AMP-015 and AMP-007 received approvals. Commentary at that time highlighted the importance of AMP-007 in supporting mid to high single digit revenue growth scenarios, tying future execution on this product to valuation support.
More recently, the tone has become more guarded. Analysts describe Amphastar’s medium term revenue trajectory as harder to model, which feeds into lower target prices and reduced conviction on the company’s ability to deliver on its 2026 outlook. Potential regulatory outcomes around AMP-004, especially regarding interchangeability, are now seen as a central swing factor for both earnings visibility and the multiple investors may be willing to pay for the stock.
The current consensus leans toward waiting for clearer evidence on execution and regulatory milestones. Investors are watching for updated guidance, AMP-004 decisions, and performance of AMP-007 and AMP-015 as the next catalysts that could either support or challenge the more conservative assumptions now embedded in several models.
Bullish Takeaways
- Bullish analysts previously set higher targets, such as US$34 and later US$30, reflecting earlier confidence that successful approvals of AMP-015 and AMP-007 could support stronger earnings power than the current price implied.
- Even after trimming targets and turning more neutral, some bullish analysts kept positive ratings while emphasizing that AMP-007 remains a key asset, with execution here viewed as important for sustaining mid to high single digit revenue growth and supporting valuation.
- These bullish views frame AMP-004’s interchangeability decision as a major potential upside catalyst, where a favorable outcome could improve revenue visibility and justify a higher multiple than what more cautious models now assume.
- Overall, bullish analysts see the recent target cuts less as a dismissal of Amphastar’s long term opportunity and more as a reset that could create room for positive surprise if the company meets its outlook and delivers on its product milestones.
What's in the News
- From October 1, 2025 to December 31, 2025, Amphastar Pharmaceuticals repurchased 806,964 shares for US$20.5 million, representing 1.74% of its shares. (Key Developments)
- Since the buyback program announced on November 8, 2016, the company has completed the repurchase of 14,913,423 shares for US$389.63 million, representing 31.42% of its shares. (Key Developments)
Valuation Changes
- Fair Value: Model fair value remains unchanged at $30.0 per share, despite other input adjustments.
- Discount Rate: The discount rate has risen slightly from 6.98% to 7.11%, indicating a modestly higher required return in the model.
- Revenue Growth: The revenue growth assumption has fallen from 6.33% to 5.86%, pointing to a more cautious outlook on top line expansion.
- Net Profit Margin: The net profit margin assumption has fallen significantly from 12.68% to 9.22%, which reduces modeled earnings power on each dollar of revenue.
- Future P/E: The future P/E multiple has risen from 13.38x to 17.31x, implying the model now uses a higher valuation multiple on projected earnings.
Key Takeaways
- Global commercialization of BAQSIMI and pipeline exclusivity could drive significant revenue and margin gains beyond current analyst expectations.
- Expanded domestic manufacturing and focus on innovative drugs position Amphastar for sustained growth, competitive advantage, and higher margins amid rising industry demand.
- Intensifying competition, revenue concentration risk, and high R&D costs threaten Amphastar's profitability as pricing pressures and generic entrants erode market share and margins.
Catalysts
About Amphastar Pharmaceuticals- A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
- While analyst consensus sees the MannKind partnership accelerating BAQSIMI's sales growth, current expectations significantly understate its potential; with Amphastar now managing global commercialization, BAQSIMI's robust volume growth and pricing power could drive materially outsized revenue and EBITDA expansion, particularly as it cannibalizes legacy glucagon products and gains share internationally.
- Analysts broadly agree that the imminent pipeline launches (AMP-002, AMP-007, AMP-015, and AMP-018) can bolster revenue and earnings, but if Amphastar captures first-to-market or sole-supplier status for AMP-007 as suggested by management, and secures early approval for AMP-002, the resulting exclusivity periods and unmet demand may lead to a step change in both top-line growth and gross margin improvement beyond consensus forecasts.
- Amphastar's aggressive quadrupling of domestic manufacturing capacity uniquely positions it to capitalize on the accelerating industry shift toward U.S.-based drug production, helping it to secure high-value contracts, mitigate global supply chain risks, and structurally enhance net margins as other companies struggle with international disruptions and tariffs.
- Demographic tailwinds-specifically, the aging global population and rising chronic disease incidence-are likely to multiply demand for Amphastar's specialty injectables and inhalation therapies over the next decade, supporting sustained double-digit revenue growth as the company broadens its branded and proprietary product offerings.
- Amphastar's intensifying focus on R&D and expansion into high-value innovative drugs, combined with its proven track record of strategic M&A, positions the company to outpace generic drug competitors, diversify revenue streams, and achieve substantial long-term earnings growth from both new internally developed and acquired proprietary products.
Amphastar Pharmaceuticals Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more optimistic perspective on Amphastar Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
- The bullish analysts are assuming Amphastar Pharmaceuticals's revenue will grow by 5.9% annually over the next 3 years.
- The bullish analysts assume that profit margins will shrink from 11.0% today to 9.2% in 3 years time.
- The bullish analysts expect earnings to reach $78.8 million (and earnings per share of $1.6) by about May 2029, down from $79.2 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 17.6x on those 2029 earnings, up from 10.2x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 14.7x.
- The bullish analysts expect the number of shares outstanding to decline by 5.17% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Intensifying competition, particularly in legacy products such as glucagon and epinephrine, has led to both price erosion and unit volume declines, which are likely to continue shrinking revenues and compressing gross margins over the long term.
- Overreliance on top-performing products like BAQSIMI and Primatene MIST increases revenue concentration risk; should demand slow, competitors enter, or pricing pressure increase, future revenues and earnings would be disproportionately affected.
- High and rising research and development expenses, up 14 percent year-over-year and driven by new proprietary projects and complex generics, may not be matched by equivalent new product revenue if regulatory delays, crowded markets, or pipeline failures occur, thus negatively impacting net margins and earnings stability.
- Flat top-line sales guidance and explicit management expectations of margin contraction due to competitive price pressures on existing products signal that earnings growth could stagnate or decline as industry-wide pricing power erodes and healthcare cost containment intensifies.
- Growing generic and biosimilar competition, particularly in crowded markets like GLP-1, as well as purchasing pressure from consolidating pharmacy benefit managers, could further erode Amphastar's market share and limit its ability to achieve future revenue and margin expansion.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bullish price target for Amphastar Pharmaceuticals is $30.0, which represents up to two standard deviations above the consensus price target of $23.33. This valuation is based on what can be assumed as the expectations of Amphastar Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $19.0.
- In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $854.7 million, earnings will come to $78.8 million, and it would be trading on a PE ratio of 17.6x, assuming you use a discount rate of 7.1%.
- Given the current share price of $18.41, the analyst price target of $30.0 is 38.6% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Amphastar Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
